Moteur de recherche d’entreprises européennes
Financement de l’UE (3 095 829 €) : ROles de l’ePitranscriptomique dans les maladies Hor16/09/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
ROles de l’ePitranscriptomique dans les maladies
Epitranscriptomics is the study of RNA modifications and their role in the regulation of gene expression. As happened for DNA, extensive covalent modification of RNA was found already in the 70s. Nevertheless, a spectacular expansion of epitranscriptomics occurred mostly in the past seven years, when an extensive layer of base decorations was discovered in mRNAs and shown to undergo cell modulation. These modifications produce programmable fluctuations in mRNA levels, translatability and subcellular compartmentalization, affecting primary cell programs such as cell differentiation and response to stress. We thus anticipate that RNA modifications will prove as important as chromatin dynamics in shaping cell phenotypes. This emerging field is hence crucial for both basic science and application to human disease. Epitranscriptomic would provide the missing link between genomic variability and cellular phenotypes, contributing to explaining the cause of specific diseases and developing novel therapies. Epitranscriptomic research is dominated by the US and China, with the EU lagging behind. We thus need to rapidly create a European framework to integrate and accelerate research efforts and industrial applications in this emerging field. To address this major European need, ROPES will train a group of Early Stage Researchers who will become the seed of the European epitranscriptome science of this decade. They will join a recently established network of academic research groups and biotech companies devoted to advancing our understanding of RNA modifications while promoting the development of new biomarkers and therapies. Focusing on RNA editing and m6A methylation, ROPES will investigate disease mechanisms and new therapies in the fields of cancer, stem cell diseases and innate immunity, while developing innovative epitranscriptomics methods. The ROPES European Training Network is the first European effort to tackle the epitranscriptome for the advancement of medicine.
| Consiglio Nazionale Delle Ricerche | 261 500 € |
| Deutsches Krebsforschungszentrum Heidelberg | 252 788 € |
| Fundacio Centre de Regulacio Genomica | 250 905 € |
| Immagina Biotechnology Srl | 261 500 € |
| Masarykova Univerzita | 234 872 € |
| Medizinische Universitaet Wien | 264 207 € |
| Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej w Warszawie | 227 479 € |
| Umea Universitet | 281 983 € |
| Universita Degli Studi Di Trento | 522 999 € |
| Universite DE Lausanne | 281 277 € |
| Universite Libre de Bruxelles | 256 320 € |
https://cordis.europa.eu/project/id/956810
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
